title: Brain atrophy and intellectual impairment in tardive dyskinesia.
abstract: Fourteen chronic schizophrenic patients with tardive dyskinesia (TD) and 13 without TD were given psychological tests and CT scans. The low density rate (LDR), i.e., the ratio of the X-ray absorption (corresponding nearly to that of cerebrospinal fluid) of a brain lesion to the X-ray absorption of the whole brain, was used as an index of brain atrophy (HN-method). The LDR of the left hemisphere of the TD patients was significantly higher than that of non-TD patients in the basal nucleus and lateral ventricle, and the LDR of the right hemisphere for the TD patients was significantly higher than that of non-TD patients in the basal nucleus. The Hasegawa Dementia Rating Scale (HDRS) and Bender-Gestalt Test (BGT) for the TD patients were significantly lower than those for the non-TD patients. Our study revealed that brain atrophy was greater in TD than in non-TD patients and tended to be more pronounced in the left hemisphere, and that the degree of intellectual impairment was greater in the TD patients than in the non-TD group. The results suggest that schizophrenic brains with TD tend to be more easily damaged than those without TD, that this tendency predominates on the left side, and that intellectual impairment in TD is related to brain atrophy.
authors.affiliation: Department of Neuropsychiatry, Faculty of Medicine, Kagoshima University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ueyama
authors.forename: H
authors.initials: H
authors.lastname: Fukuzako
authors.forename: K
authors.initials: K
authors.lastname: Takeuchi
authors.forename: K
authors.initials: K
authors.lastname: Hirakawa
authors.forename: T
authors.initials: T
authors.lastname: Fukuzako
authors.forename: Y
authors.initials: Y
authors.lastname: Hokazono
authors.forename: M
authors.initials: M
authors.lastname: Takigawa
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology*; D003072:Cognition Disorders / Q000209:etiology / Q000473:pathology; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000209:etiology / Q000473:pathology*; D005260:Female; D007839:Functional Laterality; D006801:Humans; D008297:Male; D011581:Psychological Tests; D012559:Schizophrenia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D014057:Tomography, X-Ray Computed
chemical_list: D014150:Antipsychotic Agents